88 related articles for article (PubMed ID: 27829202)
1. More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials.
Vasista A; Stockler MR; West T; Wilcken N; Kiely BE
Breast; 2017 Feb; 31():99-104. PubMed ID: 27829202
[TBL] [Abstract][Full Text] [Related]
2. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.
Kiely BE; Soon YY; Tattersall MH; Stockler MR
J Clin Oncol; 2011 Feb; 29(4):456-63. PubMed ID: 21189397
[TBL] [Abstract][Full Text] [Related]
3. Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials.
West TA; Kiely BE; Stockler MR
Eur J Cancer; 2014 Jul; 50(11):1916-24. PubMed ID: 24825113
[TBL] [Abstract][Full Text] [Related]
4. Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy.
Smith-Uffen M; Park J; Parsonson A; Kiely BE; Vasista A
Oncologist; 2024 May; ():. PubMed ID: 38768122
[TBL] [Abstract][Full Text] [Related]
5. Survival and cardiac toxicity in patients with HER2-positive, metastatic breast cancer treated with trastuzumab in routine clinical practice.
Vasista A; Ryan L; Naher S; Moylan E; Stockler MR; Wilcken N; Kiely BE
Asia Pac J Clin Oncol; 2020 Feb; 16(1):34-38. PubMed ID: 31657878
[TBL] [Abstract][Full Text] [Related]
6. Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials.
Thientosapol ES; Tran TT; Della-Fiorentina SA; Adams DH; Chantrill L; Stockler MR; Kiely BE
Intern Med J; 2013 Aug; 43(8):883-8. PubMed ID: 23656187
[TBL] [Abstract][Full Text] [Related]
7. Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials.
Kiely BE; Alam M; Blinman P; Tattersall MH; Stockler MR
Lung Cancer; 2012 Sep; 77(3):537-44. PubMed ID: 22609149
[TBL] [Abstract][Full Text] [Related]
8. Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.
Janni W; Sarosiek T; Karaszewska B; Pikiel J; Staroslawska E; Potemski P; Salat C; Brain E; Caglevic C; Briggs K; Mahood K; DeSilvio M; Marini L; Papadimitriou C
Breast; 2015 Dec; 24(6):769-73. PubMed ID: 26384789
[TBL] [Abstract][Full Text] [Related]
9. Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer.
McCaughan GJ; Blinman PL; Boyer MJ; Stockler MR
Intern Med J; 2013 Apr; 43(4):424-9. PubMed ID: 22647141
[TBL] [Abstract][Full Text] [Related]
10. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
11. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
12. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
13. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
14. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
15. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
16. Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice: a population-based study focusing on the elderly.
van Rooijen JM; de Munck L; Teeuwen GM; de Graaf JC; Jansman FG; Boers JE; Siesling S
Anticancer Drugs; 2016 Feb; 27(2):127-32. PubMed ID: 26473525
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
19. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]